Suppr超能文献

特发性肺纤维化患者肺移植的生存获益

Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis.

作者信息

Thabut Gabriel, Mal Hervé, Castier Yves, Groussard Odile, Brugière Olivier, Marrash-Chahla Rolana, Lesèche Guy, Fournier Michel

机构信息

Service de Pneumologie et Réanimation Respiratoire, Hôpital Beaujon, 100 avenue du Général Leclerc, 92110 Clichy, France.

出版信息

J Thorac Cardiovasc Surg. 2003 Aug;126(2):469-75. doi: 10.1016/s0022-5223(03)00600-7.

Abstract

OBJECTIVE

Although lung transplantation is viewed as an acceptable option for patients with end-stage idiopathic pulmonary fibrosis, the survival benefit of this approach is still debated. This study examined whether there was a survival benefit of lung transplantation in a cohort of patients referred to our transplant center with a diagnosis of idiopathic pulmonary fibrosis according to American Thoracic Society criteria.

METHODS

Forty-six patients accepted for lung transplantation during a 12-year period with a diagnosis of idiopathic pulmonary fibrosis form the basis of this study. Survival benefit offered by lung transplantation was assessed using Cox proportional-hazards modeling, with patients on a waiting list as the control group.

RESULTS

Twenty-eight patients underwent lung transplantation (27 single and 1 double), 16 patients died while waiting, and 2 patients remained on the active waiting list. Diagnosis of idiopathic pulmonary fibrosis was made on histologic examination of the explanted lung or lung biopsy before lung transplantation. There was a pattern of usual interstitial pneumonia in 31 cases (67%). The 15 remaining patients fulfilled all American Thoracic Society criteria for idiopathic pulmonary fibrosis. The median waiting time for organs was 51 days. Survival after lung transplantation was 79.4% at 1 year, 63.5% at 2 years, and 39% at 5 years. The multivariable analysis showed that lung transplantation reduced the risk of death by 75% (95% confidence interval, 8%-86%; P =.03) after adjustment on potential confounding variables.

CONCLUSIONS

Lung transplantation is effective in improving the survival of selected patients affected by idiopathic pulmonary fibrosis.

摘要

目的

尽管肺移植被视为终末期特发性肺纤维化患者的一种可接受的选择,但这种方法的生存获益仍存在争议。本研究根据美国胸科学会标准,调查了在我们移植中心被诊断为特发性肺纤维化的一组患者中,肺移植是否具有生存获益。

方法

本研究以12年间46例被接受肺移植且诊断为特发性肺纤维化的患者为基础。使用Cox比例风险模型评估肺移植提供的生存获益,将等待名单上的患者作为对照组。

结果

28例患者接受了肺移植(27例单肺移植和1例双肺移植),16例患者在等待期间死亡,2例患者仍在活跃的等待名单上。特发性肺纤维化的诊断是在肺移植前对切除的肺组织或肺活检进行组织学检查得出的。31例(67%)呈现出普通型间质性肺炎的模式。其余15例患者符合美国胸科学会关于特发性肺纤维化的所有标准。器官的中位等待时间为51天。肺移植后1年的生存率为79.4%,2年为63.5%,5年为39%。多变量分析显示,在对潜在混杂变量进行调整后,肺移植使死亡风险降低了75%(95%置信区间,8%-86%;P = 0.03)。

结论

肺移植对改善部分特发性肺纤维化患者的生存有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验